Warning letter
EzriCare LLC: warning letter of Feb 13, 2024
FDA warning letter 658390 · Division of Pharmaceutical Quality Operations I
Key facts
| Reference number | 658390 |
|---|---|
| Company | EzriCare LLC |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 13, 2024 |
| Posted date | Feb 27, 2024 |
| Issuing office | Division of Pharmaceutical Quality Operations I |
| Product type | Drugs |
| CFR sections cited | 200.50, 201.128, 200.50(a)(2) |
| Inspection city | Lakewood |
| Inspection ZIP | 08701 |
| Inspection start date | Mar 8, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: